Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkt359PMID 24051761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Physicians' Desk Reference

  2014cited by this paper
• Regulation of the cytosolic sulfotransferases by nuclear receptors

  2013cited by this paper
• Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.

  2013cited by this paper
• 2'-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine

  2013cited by this paper
• 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash.

  2013cited by this paper
• Sex-specific environmental influences on the development of autoimmune diseases.

  2013cited by this paper
• Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women

  2012cited by this paper
• Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women

  2012cited by this paper
• Insights into the Role of Bioactivation Mechanisms in the Toxic Events Elicited by Non-nucleoside Reverse Transcriptase Inhibitors

  2012cited by this paper
• The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition

  2012cited by this paper
• Possible involvement of sulfotransferase 1A1 in estragole-induced DNA modification and carcinogenesis in the livers of female mice.

  2012cited by this paper
• Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity.

  2012cited by this paper
• Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.

  2012cited by this paper
• Advances in Medicine and Biology

  2012cited by this paper
• Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.

  2011cited by this paper
• Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

  2011cited by this paper
• Mechanisms of gender-specific regulation of mouse sulfotransferases (Sults)

  2011cited by this paper
• Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

  2011cited by this paper
• Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine

  2011cited by this paper
• Sex differences in autoimmune diseases

  2011cited by this paper
• Protein adducts as prospective biomarkers of nevirapine toxicity.

  2010cited by this paper
• Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel

  2010cited by this paper
• Quantifying the Metabolic Activation of Nevirapine in Patients by Integrated Applications of NMR and Mass Spectrometries

  2010cited by this paper
• Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity.

  2010cited by this paper
• Sex Differences in UDP-Glucuronosyltransferase 2B17 Expression and Activity

  2010cited by this paper
• Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

  2009cited by this paper
• Metabolic Activation of Nevirapine in Human Liver Microsomes: Dehydrogenation and Inactivation of Cytochrome P450 3A4

  2009cited by this paper
• Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• Gender differences in pharmacological response.

  2008cited by this paper
• Gender differences in the treatment of HIV infection.

  2008cited by this paper
• Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication

  2008cited by this paper
• Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

  2008cited by this paper
• Risk for immune-mediated liver reactions by nevirapine revisited.

  2008cited by this paper
• Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine.

  2008cited by this paper
• CYP2A6 activity in a healthy Spanish population: effect of age, sex, smoking, and oral contraceptives

  2008cited by this paper
• Sex-specific differences in CYP450 isoforms in humans

  2008cited by this paper
• Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.

  2008cited by this paper
• Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts *

  2008cited by this paper
• Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.

  2008cited by this paper
• Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash.

  2008cited by this paper
• Response to antiretroviral therapy after a single, peripartum dose of nevirapine.

  2007cited by this paper
• Case-Control Exploration of Relationships Between Early Rash or Liver Toxicity and Plasma Concentrations of Nevirapine and Primary Metabolites

  2007cited by this paper
• Antiretroviral pharmacokinetic profile: a review of sex differences.

  2007cited by this paper
• Tissue distribution and ontogeny of sulfotransferase enzymes in mice.

  2006cited by this paper
• Sulfotransferase (SULT) 1A1 Polymorphic Variants *1, *2, and *3 Are Associated with Altered Enzymatic Activity, Cellular Phenotype, and Protein Degradation

  2006cited by this paper
• Nevirapine toxicity.

  2006cited by this paper
• Sex differences in pharmacokinetics and toxicity of antiretroviral therapy

  2006cited by this paper
• Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

  2005cited by this paper
• Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?

  2005cited by this paper
• No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors

  2004cited by this paper
• The Relationship between Nevirapine Plasma Concentrations and Abnormal Liver Function Tests

  2004cited by this paper
• Pharmacogenetics of soluble sulfotransferases (SULTs)

  2004cited by this paper
• Aggravation of L-DOPA-induced neurotoxicity by tetrahydropapaveroline in PC12 cells.

  2003cited by this paper
• Human 3'‐phosphoadenosine 5'‐phosphosulfate (PAPS) Synthase: Biochemistry, Molecular Biology and Genetic Deficiency

  2003cited by this paper
• Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to reduce Perinatal HIV-1Transmission in the United States

  2003cited by this paper
• Sex differences in nevirapine disposition in HIV-infected patients

  2003cited by this paper
• Pharmacogenetics of human 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 (PAPSS1): gene resequencing, sequence variation, and functional genomics.

  2003cited by this paper
• Incidence and risk factors for nevirapine-associated rash

  2003cited by this paper
• Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

  2002cited by this paper
• Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPSS2) pharmacogenetics: gene resequencing, genetic polymorphisms and functional characterization of variant allozymes.

  2002cited by this paper
• Characterization and expression of human bifunctional 3'-phosphoadenosine 5'-phosphosulphate synthase isoforms.

  2002cited by this paper
• Identification of a new subfamily of sulphotransferases: cloning and characterization of canine SULT1D1.

  2001cited by this paper
• Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.

  2001cited by this paper
• Sex differences in nevirapine rash.

  2001cited by this paper
• Gender-Based Differences in the Toxicity of Pharmaceuticals—The Food and Drug Administration's Perspective

  2001cited by this paper
• Sex-dependent regulation by dexamethasone of murine hydroxysteroid sulfotransferase gene expression.

  2001cited by this paper
• Economic Issues in the Prevention of Vertical Transmission of HIV

  2000cited by this paper
• Synthesis of Five Nevirapine Metabolites.

  2000cited by this paper
• Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

  1999cited by this paper
• Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450.

  1999cited by this paper
• Severe hepatic failure related to nevirapine treatment.

  1999cited by this paper
• Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.

  1998cited by this paper
• High incidence of nevirapine-associated rash in HIV-infected Chinese.

  1998cited by this paper
• Tissue-specific expression of rat sulfotransferase messenger RNAs.

  1998cited by this paper
• Ontogeny and hormonal basis of female-dominant rat hepatic sulfotransferases.

  1996cited by this paper

• In Silico Frontiers Shaping the Next Generation of Transformation Product Prediction and Toxicological Assessment

  2025cites this paper
• Enhancing the Maturity and Diclofenac Metabolism Ability of Mesenchymal Stem Cell‐Derived Human Hepatocytes In Vitro Using Microfluidics Technology

  2025cites this paper
• Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis

  2024cites this paper
• Antimicrobial Transformation Products in the Aquatic Environment: Global Occurrence, Ecotoxicological Risks, and Potential of Antibiotic Resistance

  2023cites this paper
• Consideration of Nevirapine Analogs To Reduce Metabolically Linked Hepatotoxicity: A Cautionary Tale of the Deuteration Approach

  2023cites this paper
• A simple method to measure sulfonation in man using paracetamol as probe drug

  2021cites this paper
• Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS.

  2021cites this paper
• The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies.

  2021cites this paper
• Nevirapine Biotransformation Insights: An Integrated In Vitro Approach Unveils the Biocompetence and Glutathiolomic Profile of a Human Hepatocyte-Like Cell 3D Model

  2020cites this paper
• Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death

  2020cites this paper
• Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity

  2019cites this paper
• In vitro assessment of competitive and time‐dependent inhibition of the nevirapine metabolism by nortriptyline in rats

  2018cites this paper
• Sex-dependent metabolism of nevirapine in rats: impact on plasma levels, pharmacokinetics and interaction with nortriptyline.

  2018cites this paper
• Development and Evaluation of Nevirapine Extended Release Tablets Using QbD Approach

  2018cites this paper
• Effects of human sulfotransferases on the cytotoxicity of 12‐hydroxynevirapine☆

  2018cites this paper
• Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge

  2017cites this paper
• Drug-Induced Liver Disease

  2017cites this paper
• Mechanisms of Drug-Induced Hepatotoxicity.

  2017cites this paper
• Nevirapine modulation of paraoxonase-1 in the liver: An in vitro three-model approach.

  2016cites this paper
• Hepatocyte spheroids as a competent in vitro system for drug biotransformation studies: nevirapine as a bioactivation case study

  2016cites this paper
• S-thiolated protein profile to assess the redox-modulation effects of antiretroviral drugs

  2016cites this paper
• Drug-induced Liver Fibrosis

  2016cites this paper
• Sex differences in hepatic and intestinal contributions to nevirapine biotransformation in rats.

  2015cites this paper
• Quinoid derivatives of the nevirapine metabolites 2-hydroxy- and 3-hydroxy-nevirapine: activation pathway to amino acid adducts

  2015cites this paper
• Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients

  2015cites this paper
• International Congress of Drug Therapy in HIV Infection 2-6 November 2014, Glasgow, UK

  2014cites this paper
• Nevirapine in an animal model of pre-diabetes: study of drug pharmacokinetic and its effects on fasting glycemia and insulin resistance

  2014cites this paper
• Sex differences in apolipoprotein A1 and nevirapine-induced

  2014cites this paper
• Sex differences in apolipoprotein A1 and nevirapine-induced toxicity

  2014cites this paper
• Optimizing antiretroviral therapy for women living with HIV

  2014cites this paper
• HDL in HIV-1 infection: a quality perspective through paraoxonase-1 activities

  2013influential citation